HHCP
VRTX icon

Hilton Head Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Hilton Head Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.8K Hold
50
– – 0.01% 441
2026
Q1 		$22.3K Hold
50
– – 0.01% 453
2025
Q4 		$22.7K Buy
+50
New +$21.6K 0.01% 435

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hilton Head Capital Partners's VRTX Position: Q2 2026 in Review

Hilton Head Capital Partners held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 50 shares worth $24.8K. The position accounts for 0.01% of the portfolio, ranked #441.

Hilton Head Capital Partners first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,749 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Hilton Head Capital Partners held 50 shares of Vertex Pharmaceuticals worth $24.8K as of Q2 2026.
  • Hilton Head Capital Partners left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Hilton Head Capital Partners's portfolio in Q2 2026, its #441 holding.
  • Hilton Head Capital Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,749 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hilton Head Capital Partners's 13F filing for Q2 2026, filed 27 Jul 2026.